ArticleMolecular therapy. Nucleic acids2025
Nanoparticle delivery of VEGF-B mRNA promotes T cell infiltration within tumor and triggers robust antitumor immunity.
Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SUMOylation in cancer: molecular mechanisms and therapeutic implications.Molecular cancer · 2026Review
- Characteristics and therapeutic resistance mechanisms of the prostate cancer immune microenvironment: a comprehensive analysis from bench to clinic.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advancement of mRNA-based cancer immunotherapies has gained significant momentum, particularly after the success of mRNA vaccines during the COVID-19 pandemic and the recognition of mRNA vaccine development with the 2023 Nobel Prize. mRNA encoding cytokines, antibodies, and chimeric antigen receptor T cells has demonstrated substantial therapeutic potential in both preclinical models and clinical trials. Previous study identified vascular endothelial growth factor B (VEGF-B) as a metabolic regulator that controls lipid synthesis and maintains mitochondrial membrane integrity, essential for the survival of activated T cells. In this study, we demonstrate that mRNA encoding VEGF-B, delivered to tumors via lipid nanoparticles, effectively controls tumor growth in both subcutaneous and lung metastasis tumor models. Combination with programmed death-1 blockade significantly amplified therapeutic efficacy, leading to complete tumor regression in the lung metastasis model. Immune profiling revealed that nanoparticle delivery of VEGF-B mRNA reprograms the tumor microenvironment by increasing CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.